Fluorescent Multivalent Opsonophagocytic Assay for Measurement of Functional Antibodies to Streptococcus pneumoniae-Reference-Cited by-同舟云学术

Fluorescent Multivalent Opsonophagocytic Assay for Measurement of Functional Antibodies to Streptococcus pneumoniae

Published:2005-10 Issue:10 Volume:12 Page:1238-1242
ISSN:1556-6811
Container-title:Clinical and Vaccine Immunology
language:en
Short-container-title:Clin Vaccine Immunol

Author:

Bieging Kathryn T.¹,Rajam Gowrisankar¹,Holder Patricia¹,Udoff Ross¹,Carlone George M.¹,Romero-Steiner Sandra¹

Affiliation:

1. Division of Bacterial and Mycotic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333

Abstract

ABSTRACT We developed fluorescent mono- and multivalent opsonophagocytic assays (fOPA and fmOPA, respectively) specific for seven Streptococcus pneumoniae serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F). Bacterial survival was quantitated with alamar blue, a fluorescent metabolic indicator. Both fOPA and fmOPA allow for determination of viability endpoints for up to seven serotypes with high levels of agreement to the reference method. The fmOPA eliminates colony counting, reduces serum volume, and produces results in 1 day.

Publisher

American Society for Microbiology

Subject

Microbiology (medical),Clinical Biochemistry,Immunology,Immunology and Allergy

Link

https://journals.asm.org/doi/pdf/10.1128/CDLI.12.10.1238-1242.2005

Reference20 articles.

1. Black, S. B., H. R. Shinefield, S. Ling, J. Hansen, B. Fireman, D. Spring, J. Noyes, E. Lewis, P. Ray, J. Lee, and J. Hackell. 2002. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr. Infect. Dis. J.21:810-815.

2. Bogaert, D., M. Sluijter, R. de Groot, and P. W. M. Hermans. 2004. Multiplex opsonophagocytosis assay (MOPA): a useful tool for the monitoring of the 7-valent pneumococcal conjugate vaccine. Vaccine22:4014-4020.

3. Capeding, M. Z. R., T. Puumalainen, C. P. Gepanayao, H. Käyhty, M. G. Lucero, and H. Nohynek. 10 August 2003, posting date. Safety and immunogenicity of three doses of an eleven-valent diphtheria toxoid and tetanus protein-conjugated pneumococcal vaccine in Filipino infants. BMC Infect. Dis.3:17. [Online.] http://www.biomedcentral.com/1471-2334/3/17 .

4. Cutts, F. T., S. M. A. Zaman, G. Enwere, S. Jaffar, O. S. Levine, J. B. Okoko, C. Oluwalana, A. Vaughan, S. K. Obaro, A. Leach, K. P. McAdam, E. Biney, M. Saaka, U. Onwuchekwa, F. Yallop, N. F. Pierce, B. M. Greenwood, and R. A. Adegbola. 2005. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomized, double-blind, placebo-controlled trial. Lancet365:1139-1146.

5. Flannery, B., S. Schrang, N. M. Bennett, R. Lynfield, L. H. Harrison, A. Reingold, P. R. Cieslak, J. Hadler, M. M. Farley, R. R. Facklam, E. R. Zell, and C. G. Whitney. 2004. Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections. JAMA291:2197-2203.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proof of concept for a single-dose Group B Streptococcus vaccine based on capsular polysaccharide conjugated to Qβ virus-like particles;npj Vaccines;2023-10-06

2. Pneumococcal Conjugate Vaccine and Pneumococcal Common Protein Vaccines;Plotkin's Vaccines;2023

3. Pneumococcal Conjugate Vaccine and Pneumococcal Common Protein Vaccines;Plotkin's Vaccines;2018

4. Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus;Journal of Immunology Research;2015

5. Glycoconjugate vaccines: an update;Expert Opinion on Biological Therapy;2014-12-11